Does Medicare Cover Rybelsus?

What is Rybelsus and which part of Medicare covers it?

Rybelsus is the brand name for oral semaglutide, a once-daily tablet taken by mouth. It belongs to a class of medicines called GLP-1 receptor agonists. The FDA first approved it in September 2019, and it was the first GLP-1 available as a pill rather than an injection.

Rybelsus is FDA-approved as an addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and also to lower the risk of serious cardiovascular events (such as heart attack and stroke) in high-risk adults who have type 2 diabetes. It comes in 7 mg and 14 mg strengths.

Original Medicare — Part A (hospital) and Part B (medical) — does not cover most outpatient prescription drugs that you take yourself at home, and that includes Rybelsus. Coverage for Rybelsus comes only through a stand-alone Medicare Part D drug plan or a Medicare Advantage plan that includes drug coverage (called an MA-PD plan).

Coverage for type 2 diabetes and heart-risk reduction

When Rybelsus is prescribed for one of its FDA-approved medical uses — controlling type 2 diabetes or reducing cardiovascular risk in high-risk adults with type 2 diabetes — it can be a covered Part D drug. Those are recognized, medically accepted indications, so plans are permitted to cover it for these reasons.

Being eligible for coverage is not the same as automatic coverage. Each Part D and MA-PD plan covers drugs through its own formulary (the plan's list of covered medicines). Whether your specific plan covers Rybelsus, and how much you pay, depends on that plan's formulary and the cost tier it places the drug on.

Why Medicare won't cover Rybelsus for weight loss

Federal law specifically excludes from Part D coverage any "agents when used for anorexia, weight loss, or weight gain." CMS interprets this to mean a drug used for weight loss is not a covered Part D drug, even if the same drug would be covered for a different, approved use.

Because of this rule, if Rybelsus is prescribed off-label simply to help someone lose weight, Medicare Part D cannot pay for it. The deciding factor is the reason it is prescribed, not the drug itself. Note that Rybelsus is FDA-approved for diabetes and heart-risk reduction — it is not FDA-approved as a weight-loss drug.

• Covered (if on your plan's formulary): Rybelsus for type 2 diabetes
• Covered (if on your plan's formulary): Rybelsus to reduce cardiovascular risk in high-risk adults with type 2 diabetes
• Not covered: Rybelsus prescribed purely for weight loss (statutory Part D exclusion)

What Rybelsus costs with Medicare in 2026

Your out-of-pocket cost for Rybelsus depends entirely on your plan: its monthly premium, its deductible, and the copay or coinsurance tier it assigns to the drug. Because tiers and prices differ from plan to plan, the only reliable way to know your cost is to look up Rybelsus in your plan's formulary or use the Medicare Plan Finder at Medicare.gov.

A few 2026 figures help frame the overall picture. The Part D national base beneficiary premium is $38.99 per month, though actual plan premiums vary widely. Higher-income beneficiaries may also pay a Part D IRMAA surcharge of $14.50 to $91.00 per month, which kicks in above 2024 income (MAGI) of $109,000 for a single filer or $218,000 for a joint return.

Starting in 2026, Part D has a hard annual cap on what you pay out of pocket for covered drugs: $2,100. Once your spending on covered Part D drugs (which can include Rybelsus when it is covered) reaches $2,100 for the year, you pay $0 for covered drugs for the rest of that year.

If your income and resources are limited, the Extra Help program (the Part D Low-Income Subsidy) can sharply cut your costs. In 2026, people who qualify pay no more than $12.65 for each covered brand-name drug. The 2026 income limits in the 48 states and DC are $23,475 for an individual and $31,725 for a married couple, and the 2026 resource (asset) limits are $18,090 for a single beneficiary and $36,100 for a married couple living together.

Prior authorization, formularies, and checking your plan

Part D plans use management tools to control how drugs are covered. For Rybelsus, plans commonly require prior authorization, meaning your doctor must get the plan's approval before it will pay. A plan may also apply step therapy (requiring you to try another drug first) or quantity limits.

Each plan publishes its own formulary and sets its own copays and coinsurance, so coverage and cost genuinely vary from one plan to the next. To confirm whether your plan covers Rybelsus and what you will pay, look up the drug in your plan's formulary or use the Medicare Plan Finder. If you are choosing a plan, this is worth checking before you enroll.

The 2026 GLP-1 Bridge, late penalties, and appeals

You may have heard about a new Medicare GLP-1 coverage option. Beginning July 1, 2026, a voluntary Medicare GLP-1 Bridge lets eligible Part D beneficiaries get certain GLP-1 drugs for weight loss for a $50 monthly copayment. Importantly, the covered list is limited to Wegovy (all formulations), the Zepbound KwikPen, and Foundayo — Rybelsus is not included in the GLP-1 Bridge.

If you delay joining a Part D plan and go without other creditable drug coverage, you can face a Part D late-enrollment penalty if you later need a plan to cover Rybelsus. The penalty is 1% of the national base beneficiary premium ($38.99 in 2026) times the number of full months you went without coverage, rounded to the nearest $0.10, and it is added to your premium for as long as you have Part D.

If your plan denies coverage for Rybelsus, you have the right to act. You (or your doctor) can request a coverage determination or formulary exception, and if that is denied you can appeal. Ask your plan how to file, and gather a statement from your prescriber explaining the medical need — for example, that the drug is for your type 2 diabetes or heart-risk reduction, not weight loss.